Research Paper Volume 12, Issue 17 pp 17694—17712
Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells
Figure 1. Acquired Enz-resistance after Doc-resistance in DocRPC cells. (A) The growth curve of DocR1_CWR22Rv1 cells after 6 days 20 μM Enz treatment. DocR1_CWR22Rv1 cells (middle) are more resistant to Enz treatment than DocS1_CWR22Rv1 cells (upper), with 38% vs 58% growth reduction. Survival rate (lower) under Enz treatment at Day 6 (DocR1 vs DocS1 cells). (B) The growth curve of DocR2_CWR22Rv1 cells after 6 days 20 μM Enz treatment. DocR2_CWR22Rv1 cells (middle) are more resistant to Enz treatment than DocS1_CWR22Rv1 cells (upper), with 36% vs 59% reduction. Survival rate (lower) under Enz treatment at Day 6 (DocR2 vs DocS2 cells). (C) The growth curve of DocR3_C4-2 cells after 6 days 15 μM Enz treatment. DocR3-C4-2 cells (middle) are more resistant to Enz treatment than DocS3_C4-2 cells (upper), with 77% vs 100% reduction. Survival rate (lower panel) under Enz treatment at Day 6 (DocR3 vs DocS3 cells). Results are mean ± SD compared to controls *p<0.05; ***p<0.001.